Targovax ASA ( (GB:0RIS) ) has provided an update.
Circio Holding ASA has successfully raised awareness of its circular RNA technology, achieving significant media coverage in over 50 articles and interviews across leading life science publications. This strategic effort has enhanced the company’s visibility and validated its circVec platform, which is poised to become a standard in nucleic acid and viral therapeutics, potentially impacting stakeholders from biotech executives to academic scientists.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced circular RNA vector expression technology for next-generation nucleic acid medicine. The company has created a unique circRNA vector expression platform, circVec, which offers enhanced and durable protein expression compared to traditional mRNA systems. Circio is also developing a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
YTD Price Performance: -93.96%
Average Trading Volume: 23,211
Technical Sentiment Consensus Rating: Buy
Current Market Cap: NOK53.07M
For an in-depth examination of 0RIS stock, go to TipRanks’ Stock Analysis page.